Shares of Paladin Labs Inc. soared 49.4 percent Tuesday on news of an acquisition by Endo Health Solutions for $1 .6 billion in stock and cash. The merger will marry Paladin’s pipeline of products in attention deficit hyperactivity disorder, pain, urology and allergy with Endo’s health care assets under a newly formed entity based in Ireland, led by Endo’s management team.